Goldman Sachs Reiterates Buy Rating on Exact Sciences (EXAS) following GH's ECLIPSE trial
Tweet Send to a Friend
Goldman Sachs analyst Matthew Sykes reiterated a Buy rating and $65.00 price target on Exact Sciences (NASDAQ: EXAS) after weak ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
